Welcome to our dedicated page for Remsleep Holding SEC filings (Ticker: RMSL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a micro-cap medical device firm like REMSleep Holdings is challenging—the company’s SEC disclosures mix FDA milestones, prototype costs, and insider funding rounds into dense documents. If you have ever searched for “REMSleep Holdings insider trading Form 4 transactions” or tried to decode an 8-K about a new clinical test, you know the struggle of wading through technical language.
Stock Titan solves that problem in seconds. Our platform streams every filing—10-K annual reports, 10-Q quarterly earnings, 8-K material events, and Form 4 insider trades—in real time from EDGAR and layers on AI-powered summaries. Want the highlights of a “REMSleep Holdings quarterly earnings report 10-Q filing”? Curious about “REMSleep Holdings executive stock transactions Form 4” before a product announcement? The answers are surfaced for you, with plain-English explanations and direct links to page numbers.
Here’s what investors uncover:
- Cash flow details tied to CPAP R&D in the “REMSleep Holdings annual report 10-K simplified”.
- Real-time alerts for “REMSleep Holdings Form 4 insider transactions real-time” that may hint at management’s confidence.
- FDA 510(k) updates inside 8-K filings—“REMSleep Holdings 8-K material events explained” by AI so you grasp the regulatory path.
- Board pay packages from the “REMSleep Holdings proxy statement executive compensation”.
Whether you are comparing quarter-over-quarter compliance costs, monitoring “REMSleep Holdings earnings report filing analysis”, or simply “understanding REMSleep Holdings SEC documents with AI”, Stock Titan delivers concise insights, saving hours and ensuring you never miss a critical disclosure.
REMSleep Holdings (RMSL) reported Q3 2025 results showing a much larger loss while beginning sales of its DeltaWave CPAP interface. Revenue for the quarter was $7,454, down from $37,260 a year earlier, and the quarterly net loss widened to $2,312,146. For the first nine months of 2025, revenue was $12,278 versus $122,735 in 2024, with a net loss of $2,685,406 and an accumulated deficit of $17,956,162.
Results were heavily affected by a $2,160,000 non-cash compensation expense from issuing Series C preferred stock to the CEO and a related party. The company relies on multiple convertible promissory notes from 1800 Diagonal, which generated significant interest expense and share issuances totaling 73,214,713 shares in the period. At September 30, 2025, cash was $343,948 and net cash used in operating activities was $373,395. Management states there is substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 1,617,658,094 as of November 18, 2025.
RemSleep Holdings, Inc. filed a Form 12b-25 to notify a late filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company cites the need for additional time for its independent registered public accounting firm to complete its review.
RemSleep states it intends to file the Form 10-Q by or before November 19, 2025, consistent with the Rule 12b-25 provision that permits a five-calendar-day extension for quarterly reports.
FAQ
What is the current stock price of Remsleep Holding (RMSL)?
What is the market cap of Remsleep Holding (RMSL)?
